All In Biotech

Drug Trial Radar · NCT04867317

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

CSP #2018 - Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 172 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

172

Planned (sponsor's estimate)

Start

Jan 13, 2025

Primary completion

Feb 28, 2027

Study completion Sep 30, 2029

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Apr 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild traumatic brain injury (mTBI).

Conditions

  • Adult Growth Hormone Deficiency
  • Mild Traumatic Brain Injury

Interventions

  • SomatropinDrug

    Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.

  • PlaceboOther

    Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QoL-AGHDA (Quality of Life-Assessment of Adult Growth Hormone in Adults)Time frame: 6 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Birmingham VA Medical Center, Birmingham, AL

    Birmingham, Alabama · Not yet recruiting

  • Phoenix VA Health Care System, Phoenix, AZ

    Phoenix, Arizona · Not yet recruiting

  • VA San Diego Healthcare System, San Diego, CA

    San Diego, California · Not yet recruiting

  • Rocky Mountain Regional VA Medical Center, Aurora, CO

    Aurora, Colorado · Recruiting

  • Washington DC VA Medical Center, Washington, DC

    Washington D.C., District of Columbia · Not yet recruiting

  • Atlanta VA Medical and Rehab Center, Decatur, GA

    Decatur, Georgia · Active not recruiting

  • VA Ann Arbor Healthcare System, Ann Arbor, MI

    Ann Arbor, Michigan · Recruiting

  • Minneapolis VA Health Care System, Minneapolis, MN

    Minneapolis, Minnesota · Recruiting

  • Kansas City VA Medical Center, Kansas City, MO

    Kansas City, Missouri · Not yet recruiting

  • Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE

    Omaha, Nebraska · Not yet recruiting

  • Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC

    Salisbury, North Carolina · Not yet recruiting

  • Oklahoma City VA Medical Center, Oklahoma City, OK

    Oklahoma City, Oklahoma · Not yet recruiting

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX

    Dallas, Texas · Not yet recruiting

  • Michael E. DeBakey VA Medical Center, Houston, TX

    Houston, Texas · Recruiting

  • South Texas Health Care System, San Antonio, TX

    San Antonio, Texas · Not yet recruiting

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.